Humacyte (NASDAQ:HUMA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report published on Friday morning, MarketBeat Ratings reports. HC Wainwright currently has a $15.00 price target on the stock, up from their prior price target of $12.00.

Several other research firms have also issued reports on HUMA. TD Cowen reaffirmed a "buy" rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a "strong-buy" rating in a report on Monday, September 9th. BTIG Research restated a "buy" rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Benchmark reiterated a "buy" rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Finally, Piper Sandler set a $6.00 price target on Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $13.43.

Humacyte Stock Up 34.1 %

NASDAQ:HUMA traded up $1.18 on Friday, hitting $4.64. 75,231,266 shares of the company's stock were exchanged, compared to its average volume of 2,735,148. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a 50-day moving average price of $4.85 and a 200-day moving average price of $5.87. The company has a market cap of $583.99 million, a P/E ratio of -3.46 and a beta of 1.38. Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 in the last 90 days. Company insiders own 11.20% of the company's stock.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new position in shares of Humacyte during the second quarter worth $28,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte in the 3rd quarter worth about $75,000. Principal Financial Group Inc. acquired a new position in Humacyte in the 2nd quarter worth about $83,000. FORA Capital LLC bought a new position in Humacyte in the third quarter valued at about $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the second quarter valued at about $97,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.